保留子宫的子宫腺肌病治疗研究核心结局集与结局定义(COSAR):国际多利益相关方改良德尔菲共识研究
本研究通过2021年3月至12月的国际多利益相关方改良德尔菲共识流程,纳入150名医疗专业人员、17名研究人员及334名有子宫腺肌病亲身经历者或伴侣(来自48个国家),最终确定涵盖九大领域的24个特异性与26个通用核心结局,并为每个结局提供定义,旨在规范未来保留子宫干预研究的结果报告。
要点
- 最终核心结局集包含9个领域的24个特异性与26个通用核心结局,所有结局均由指导委员会提供定义。
- 其中19个结局仅适用于特定研究类型,指导委员会还建议记录3个卫生经济学结局(未纳入核心结局集)。
- 该核心结局集适用于所有研究保留子宫干预措施治疗子宫腺肌病的临床研究,以改善报告质量并促进证据合成。
核心结论
- 最终核心结局集包含9个领域的24个特异性与26个通用核心结局,所有结局均由指导委员会提供定义。
- 指导委员会建议记录3个卫生经济学结局,但未将其纳入核心结局集。
研究设计与样本
- 国际共识制定流程于2021年3月至2021年12月进行。
- 第一轮参与者包括来自48个高收入、中等收入及低收入国家的150名医疗专业人员、17名研究人员和334名有子宫腺肌病亲身经历者或伴侣;第二轮有291名参与者。
- 核心环节为两步改良德尔菲电子调查,指导委员会通过半结构化会议分析结果并形成最终核心结局集。
主要发现
- 共识别241个结局,并提炼为71个潜在结局的「长列表」。
- 最终核心结局集涵盖疼痛、子宫出血、生殖结局、血液学、泌尿系统、生活影响、照护提供、不良事件及报告条目九个领域。
- 24个特异性核心结局与26个通用核心结局均附有指导委员会提供的定义。
- 其中19个结局仅适用于特定研究类型。
关键数值与推荐
- 核心结局集包含9个领域的24个特异性与26个通用核心结局。
- 19个结局仅适用于特定研究类型。
- 指导委员会建议记录3个卫生经济学结局,但不纳入核心结局集。
临床怎么用
- 作者认为,在未来子宫腺肌病治疗研究中实施该核心结局集将改善报告质量并有助于证据合成。
局限性
- 来自欧洲以外大陆的患者在本调查中代表性不足。
- 调查缺乏翻译可能限制了非英语国家人员的积极参与。
- 仅58%的参与者返回了第二轮,但分析未提示存在失访偏倚。
- 关于哪些症状由子宫腺肌病引起、何时与其他共存疾病(如子宫内膜异位症)相关,科学证据显著缺乏。
- 随着未来研究提供更多清晰信息,将有必要对核心结局集进行适当审查与修订。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What outcomes should be reported in all studies investigating uterus-sparing interventions for treating uterine adenomyosis? SUMMARY ANSWER: We identified 24 specific and 26 generic core outcomes in nine domains. WHAT IS KNOWN ALREADY: Research reporting adenomyosis treatment is not patient-centred and shows wide variation in outcome selection, definition, reporting and measurement of quality. STUDY DESIGN, SIZE, DURATION: An international consensus development process was performed between March and December 2021. Participants in round one were 150 healthcare professionals, 17 researchers and 334 individuals or partners with lived experience of adenomyosis from 48 high-, middle- and low-income countries. There were 291 participants in the second round. PARTICIPANTS/MATERIALS, SETTING, METHODS: Stakeholders included active researchers in the field, healthcare professionals involved in diagnosis and treatment, and people and their partners with lived experience of adenomyosis. The core component of the process was a 2-step modified Delphi electronic survey. The Steering Committee analysed the results and created the final core outcome set (COS) in a semi-structured meeting. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 241 outcomes was identified and distilled into a 'long list' of 71 potential outcomes. The final COS comprises 24 specific and 26 generic core outcomes across nine domains, including pain, uterine bleeding, reproductive outcomes, haematology, urinary system, life impact, delivery of care, adverse events and reporting items, all with definitions provided by the Steering Committee. Nineteen of these outcomes will apply only to certain study types. Although not included in the COS, the Steering Committee recommended that three health economic outcomes should be recorded. LIMITATIONS, REASONS FOR CAUTION: Patients from continents other than Europe were under-represented in this survey. A lack of translation of the survey might have limited the active participation of people in non-English speaking countries. Only 58% of participants returned to round two, but analysis did not indicate attrition bias. There is a significant lack of scientific evidence regarding which symptoms are caused by adenomyosis and when they are related to other co-existent disorders such as endometriosis. As future research provides more clarity, the appropriate review and revision of the COS will be necessary. WIDER IMPLICATIONS OF THE FINDINGS: Implementing this COS in future studies on the treatment of adenomyosis will improve the quality of reporting and aid evidence synthesis. STUDY FUNDING/COMPETING INTEREST(S): No specific funding was received for this work. T.T. received a grant (grant number 2020083) from the South Eastern Norwegian Health Authority during the course of this work. T.T. receives personal fees from General Electrics and Medtronic for lectures on ultrasound. E.R.L. is the chairman of the Norwegian Endometriosis Association. M.G.M. is a consultant for Abbvie Inc and Myovant, receives research funding from AbbVie and is Chair of the Women's Health Research Collaborative. S.-W.G. is a board member of the Asian Society of Endometriosis and Adenomyosis, on the scientific advisory board of the endometriosis foundation of America, previous congress chair for the World Endometriosis Society, for none of which he received personal fees. E.S. received outside of this work grants for two multicentre trials on endometriosis from the National Institute for Health Research UK, the Rosetrees Trust, and the Barts and the London Charity, he is a member of the Medicines and Healthcare Products Regulatory Agency (MHRA), Medicines for Women's Health Expert Advisory Group, he is an ambassador for the World Endometriosis Society, and he received personal fees for lectures from Hologic, Olympus, Medtronic, Johnson & Johnson, Intuitive and Karl Storz. M.H. is member of the British Society for Gynaecological Endoscopy subcommittee. No other conflict of interest was declared. TRIAL REGISTRATION NUMBER: N/A.
引用
- Tellum T, Naftalin J, Chapron C, et al. Development of a core outcome set and outcome definitions for studies on uterus-sparing treatments of adenomyosis (COSAR): an international multistakeholder-modified Delphi consensus study. Hum Reprod. 2022. PMID: 35906919. doi:10.1093/humrep/deac166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。